Abstract In this work, we aimed to investigate the effects of long-term supplementations with L-glutamine or L-alanyl-L-glutamine in the high-fat diet (HFD)-fed B6.129SF2/ J mouse model over insulin sensitivity response and signaling, oxidative stress markers, metabolism and HSP70 expression. Mice were fed in a standard low-fat diet (STA) or a HFD for 20 weeks. In the 21th week, mice from the HFD group were allocated in five groups and supplemented for additional 8 weeks with different amino acids: HFD control group (HFD-Con), HFD ? dipeptide L-alanyl-Lglutamine group (HFD-Dip), HFD ? L-alanine group (HFD-Ala), HFD ? L-glutamine group (HFD-Gln), or the HFD ? L-alanine ? L-glutamine (in their free forms) group (HFD-Ala 1 Gln). HFD induced higher body weight, fat pad, fasted glucose, and total cholesterol in comparison with STA group. Amino acid supplementations did not induce any modifications in these parameters. Although insulin tolerance tests indicated insulin resistance in all HFD groups, amino acid supplementations did not improve insulin sensitivity in the present model. There were also no significant differences in the immunocontents of insulin receptor, Akt, and Toll-like receptor-4. Notably, total 70 kDa heat shock protein (HSP72 ? HSP73) contents in the liver was markedly increased in HFD-Con group as compared to STA group, which might suggest that insulin resistance is only in the beginning. Apparently, B6.129SF2/J mice are more resistant to the harmful effects of HFD through a mechanism that may include gut adaptation, reducing the absorption of nutrients, including amino acids, which may explain the lack of improvements in our intervention.
Introduction
Dietary fat plays a major role in obesity and, when in excess, is linked with the development of several chronic health problems, such as obesity, dyslipidemia, hyperglycemia, hypertension, and type 2 diabetes mellitus (T2DM) [1, 2] . Therefore, high-fat diets (HFD) providing at least 30 % of total calories as lipids constitute a very useful model of human disease [3] . Chronic excess of available saturated fatty acids in the diet can induce obesity and a state of low-grade inflammation, which is the hallmark for T2DM and cardiovascular diseases (CVD) [4] [5] [6] . The inflammatory effect of saturated fatty acids was found to be partially mediated by their binding to Toll-like receptors (TLRs), particularly of 2 and 4 types (TLR2 and TLR4, respectively), turning on pro-inflammatory pathways that can activate serine/threonine kinases such as c-Jun N-terminal kinases (JNKs) and protein kinase C (PKC), both inhibitors of the insulin signaling, thus promoting insulin resistance [7] [8] [9] . Adipose tissue expansion and senescence increase the levels of free fatty acids (FFA) and pro-inflammatory cytokines in the circulation, which together with hyperglycemia and altered lipoprotein profiles, increases the synthesis and accumulation of intramyocellular triacylglycerols, resulting in an enhanced synthesis of toxic fatty-acid-derived metabolites [4, 10] . These metabolites may cause an elevation in the production of reactive oxygen and nitrogen species (ROS and RNS, respectively), resulting in oxidative stress, mitochondrial dysfunction, and the activation of stress-associated transcription factors, such as NF-jB, followed by the increased production and release of pro-inflammatory cytokines [4] .
As recently suggested, heat shock proteins of the 70 kDa family (particularly, HSP72 a.k. as HSP70, encoded by the HSPA1A gene in humans) are key regulators of inflammation (by acting as anti-inflammatory protein chaperones) and insulin sensitivity [11] [12] [13] . The protective role of intracellular HSP70 on inflammation and maintenance of insulin signaling is achieved through its ability to directly inhibit the activation of JNKs and NF-jB [14] and also by stabilizing the insulin receptor [15] and its downstream signaling molecules, such as Akt [16, 17] . Remarkably, body fat composition can determine the content of HSP70 [18] . Apparently, HSP70 level are negatively correlated with body fat content and positively correlated with insulin sensitivity in obese human subjects [19] . The importance of HSP70 for insulin sensitivity was also well demonstrated by the observation that diabetic monkeys present lower HSP70 content and that glucose tolerance is reestablished by the induction of HSP70 expression [20] . Thus, strategies to increase intracellular HSP70 content could reduce insulin resistance caused by obesity.
Interestingly, some nutrients, such as L-glutamine and Lalanyl-L-glutamine dipeptide were shown to potentiate the expression of HSP70 [21] [22] [23] . Thus, amino acid supplementations may be useful tools to enhance HSP70 expression, decreasing inflammation, and improving insulin sensitivity. Hence, in this work, we analyzed the effects of long-term (8 weeks) L-glutamine and L-alanyl-L-glutamine supplementation in the HFD-fed B6.129SF2/J mouse model of the insulin resistance.
The choice of the proposed model merits a brief explanation. The currently ''classical'' model of HFD-induced insulin resistance and type 2 diabetes in rodents was described in C57BL/6J mice by Winzell and Ahrén [24] . Indeed, many previous studies have approached the susceptibility of the C57BL/6J mouse strain to the development of insulin resistance, including those in which Lglutamine supplementations were evaluated [25] . On the other hand, our group has a specific interest in knowing B6.129SF2/J mouse behavior under HFD regimen because this strain is considered to be the best control strain for the well known The Jackson Laboratory's B.129S7-Ldlr tm1Her / J mouse model for diet-induced atherosclerosis which has been being under evaluation in our lab for many years [26] . The B6.129SF2/J mouse strain studied herein was bred from pairs of B6.129SF1/J mice which, in turn, were previously obtained by breeding pairs of C57BL/6J (female) and 129S1/SvImJ (male) mice. Previous studies from other laboratories have firmly demonstrated that C57BL/6J mice dramatically differ from 129S strains in their susceptibility for developing insulin resistance and diabetes under HFD, this being associated with enhanced PKCd expression in the liver of the former as compared to the latter [27] . Moreover and noteworthily, this difference in PKCd expression is supposed to be responsible for the enhanced hepatosteatosis observed in both mice and humans, and may explain, at least in part, the marked suppression in HSP70 pathways we have recently observed in obese humans [28] .
Hence, in the present study we tested glutamine supplementations in B6.129SF2/J mice under a HFD chow, evaluating glucose homeostasis, insulin sensitivity response and signaling, oxidative stress markers, and HSP70 expression in the liver and skeletal muscle.
Materials and methods

Materials
All the chemicals were purchased from Sigma-Aldrich (St. Louis, USA) unless otherwise stated.
Animals
B6.129SF2/mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and inbred at The Federal University of Rio Grande do Sul Institute of Basic Health Sciences Animal Care Facility (CREAL). Male (3 months old) mice were maintained under standard conditions with a 12 h light/dark cycle having free access to food and water. The mice were housed in plastic cages (33 9 17 9 40 cm), in an atmosphere of 50-60 % relative humidity and temperature 25 ± 2°C. All the procedures performed in studies involving the animals followed the ethical rules established by Arouca's Act 
Experimental design
Mice were randomly allocated into two groups (n = 48 each): standard diet-fed group (STA) or high-fat diet-fed group (HFD), receiving the specific diet for 20 weeks before any supplementation test. The STA group received a standard pelleted diet (Nuvilab CR-1, commercially obtained from Nuvital Nutrientes SA; total metabolizable energy: 16.6 MJ/kg, being 11.4 % as fats, 62.8 % as carbohydrates and 25.8 % as proteins). The HFD group was provided with a lard-based HFD (total metabolizable energy: 22.8 MJ/kg, being 58.3 % as fats, 24.5 % as carbohydrates, and 17.2 % as proteins) [24] . All diet ingredients in the HFD (except for starch and lard) were adjusted to be present at the same amount as in the STA group. Body mass were recorded and oral glucose tolerance test (OGTT) was performed every 4 weeks in both groups.
On the 21th week, mice from the HFD group were divided into additional five groups (n = 8): HFD control group (HFD-Con), HFD ? dipeptide L-alanyl-L-glutamine group (HFD-Dip), HFD ? L-alanine group (HFD-Ala), HFD ? L-glutamine group (HFD-Gln) or HFD L-alanine ? L-glutamine in their free forms group (HFDAla 1 Gln). The animals were supplemented by gavage six times a week during 8 weeks. Animals in the supplementation groups received daily: HFD-Con (water); HFDDip (1.5 g of dipeptide L-alanyl-L-glutamine/kg body weight); HFD-Ala (1.85 g of L-alanine/kg body weight); HFD-Gln (1.51 g of L-glutamine/kg body weight), and HFD-Ala ? Gln (0.62 g of L-alanine/kg plus 1 g of Lglutamine in their free forms/kg body weight). All doses were isonitrogenous [21] . Figure 1 illustrates the experimental design.
Diet intake in all HFD groups was recorded once a week. On the 28th week, glucose tolerance tests were performed: orally (OGTT) or intraperitoneally (IPGTT). Insulin tolerance tests (ITT) were also carried out. On the 29th week, the animals were killed by decapitation for blood collection into heparinized tubes. Plasma was obtained from blood samples after centrifugation (8509g for 10 min) and stored at 4°C. Adipose tissue, liver, and soleus muscle were immediately excised, washed in PBS and stored in liquid nitrogen.
Glucose and insulin tolerance test
Glucose was given by gavage (OGTT) (10 g/kg) or injected intraperitoneally (IPGTT) (1 g/kg) to overnight fasted mice, and glycemia was measured using a glucometer (On Call Plus, Acon Laboratories Inc.) at time 0, 30, 60, 90, and 120 min after glucose administration. Insulin tolerance tests (ITT) were performed in 6 h fasted mice. Basal glycemia was measured before the insulin injection (0.75 IU/ kg body weight; Novolin Ò Novo Nordisk), after 15, 30, and 45 min. For both tests, the incremental areas under the curves (AUC) were calculated.
Biochemical analyses in plasma and tissues
Total cholesterol (COL) and triacylglycerol (TAG) levels were quantified in sera using commercial kits (Bioclin Ò ). Intracellular L-glutamine and L-glutamate concentrations were determined in skeletal muscle lysates using GLN-1 Glutamine and Glutamate Determination kit (SigmaAldrich) as described by Lund [29] . For the estimative assessment of oxidative stress-induced lipoperoxide formation, thiobarbituric acid-reactive substances (TBA-RS) assay was performed in acetic acid homogenates of samples to precipitate proteins and to acidify samples. This mixture was then centrifuged (10009g for 3 min). TBA (0.67 % w/v) was added to the reaction medium, and tubes were boiled (100°C) for 1 h. Absorbance was read at 535 nm in a spectrophotometer. Results were expressed as micromoles per milligram of protein [30] . Livers were prepared and assayed for total glutathione (GSH) content as described in Kolberg et al. [31] . Briefly, liver was disrupted in metaphosphoric acid (MPA) 5 % (w/v) on ice. After centrifugation (16,0009g for 2 min at room temperature), cell lysates were spectrophotometrically (415 nm) assayed on a microplate reader (Bio-Rad) by modification of the 5,5 0 -dithiobis-(2-nitrobenzoic acid) [DTNB, Sigma]/GSSG reductase (Sigma) recycling method.
For glycogen analysis, 100-200 mg of freeze-dried liver samples were incubated in 30 % (w/v) KOH for 20 min at 100°C. The solution was cooled and ethanol-precipitated being, subsequently, heated for 10 min at 65°C. After centrifugation (10009g, 5 min), the pellet was washed with ethanol, and water was added. The samples and a parallel glycogen curve were heated for 1 h at 100°C with 4 N HCl to hydrolyze glycogen into glucosyl units [32] . The solution was subsequently neutralized with an equal volume of 2.0 N Na 2 CO 3 , and analyzed for glucose contents using an enzymatic assay (kit Analisa Ò ). Protein concentration was determined by the Bradford's method using fraction V bovine serum albumin (BSA, Sigma) as standard [33] .
Western blotting
Liver (1:10 w/v) and soleus muscle (1:5 w/v) were prepared as described above and processed for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analyses as adapted from elsewhere [18, 31, 34] . Briefly, the tissues were homogenized (still frozen) in 0.1 % (w/v) SDS buffer containing protease and phosphatase inhibitor cocktail (Sigma) consisting of (final concentrations) leupeptin (4.2 lM), aprotinin (0.31 lM), N-tosyl-L-lysine chloromethyl ketone (TLCK, hydrochloride; 20 lM), phenyl-methyl-sulfonyl fluoride (PMSF, 100 lM), sodium orthovanadate (Na 3 VO 4 ; 1 mM), sodium molybdate (Na 2 MoO 4 ; 1 mM), and b-glycerophosphate (1 mM). Afterward, the homogenates were centrifuged at 150009g for 5 min at room temperature, and the supernatant fractions were saved for protein determination [33] by using BSA (Sigma) as standard. Then, equivalent amounts of protein from each sample (*40 lg) were mixed with Laemmli's gel loading buffer [50 mM . The membranes were incubated overnight with mouse anti-HSP70 monoclonal antibody (Sigma H5147), which recognizes both the 73 kDa constitutive HSC70 (hspa8 gene) and the 72 kDa inducible HSP70 (hspa1a gene) forms. Total (quiescent unphosphorylated plus activated phosphorylated) insulin receptor (IR) were revealed with rabbit anti-IR polyclonal antibody (Sigma SAB4501555) and rabbit anti-IR-P polyclonal antibody (Sigma I1783). Activated phosphorylated Akt (pAkt) was detected with rabbit anti-pAkt polyclonal antibody (Sigma SAB4300574), and TLR4 with rabbit anti-TLR4 polyclonal antibody (Sigma PRS3141).
Peroxidase-labeled rabbit anti-mouse IgG (Sigma A9044) or goat anti-rabbit IgG (whole molecule)-biotin antibody (Sigma B8895) followed by streptavidin-peroxidase polymer ultrasensitive (Sigma S2438) were utilized as secondary antibodies and enhancing reagent, respectively. As gel loading control, peroxidase-labeled rabbit anti-GAPDH polyclonal antibody (Sigma G9545) was used. Visualization of the blots was performed for 300 s by using chemiluminescence reagent p-coumaric acid and luminol, in ImageQuant TM 350 chemiluminescence system (GE) and the accompanying online stacking imaging software ImageQuant TL 7.0 (GE). Data are given as the means ± SEM of immunocontents normalized in terms of GAPDH, unless otherwise stated.
Statistical analysis
As demanded in each case, data were analyzed by Student's t test or one-way analysis of variance (ANOVA) followed by Student Newman-Keuls Test (SNK), after Kolmogorov-Smirnov test for normality, using GraphPad Prism 5.0. P values of at least 0.05 were considered significant.
Results
Physiological and biochemical parameters
No differences in food intake or the average weekly energy intake (in kJ/animal) were found between the groups (data not shown). As expected, after 28 weeks of treatment, the HFD animals showed higher body weight, fat pad, fasting glucose, and total cholesterol in comparison with the animals of the STA group (Table 1) . Surprisingly, in the present model, HFD mice showed a decrease in liver TBA-RS. No changes were found in TAG, liver glycogen, and liver GSH (Table 1) . On the other hand, although HFD were found to be obese, amino acid supplementations did not induce any modifications in body weight, fat pad, TAG, total cholesterol, muscle L-glutamine, liver glycogen, liver TBA-RS, and liver total glutathione (Table 2) .
Insulin sensitivity and response
ITT data clearly indicated insulin resistance in all HFD groups (Fig. 2c) . However, the different amino acid supplementations did not improve insulin sensitivity in any of the test groups. Regarding the glucose tolerance, the HFDCon, HFD-Dip, HFD-Ala, HFD-Gln, and HFD-Ala ? Gln groups showed no difference in OGTT (Fig. 2a) or IPGTT (Fig. 2b) in comparison to the STA group. It is important to mention that, during the OGTT, it is expected that glycemia peaks 30 min after glucose administration, as found for STA group (Fig. 2a) . Interestingly, in all HFD groups of the present model, this peak was absent in oral tests, suggesting differential glucose absorption by the gut.
In fact, when we tested IPGTT, the 30 min peak was present in all groups (Fig. 2b) .
Protein expressions
In order to evaluate the molecular basis of insulin resistance in this mouse model, total, and phosphorylated forms of the insulin receptor and the phosphorylated Akt expressions were determined in soleus muscle and liver. Again, no statistical difference was observed between the groups (Fig. 3) . There was also no difference in protein content of TLR4 (Fig. 4) . Notably, total HSP70 (HSP72 ? HSP73) protein contents in liver were markedly increased in HFD-Con group as compared to STA group. Amino acid supplementations did not change any of the analyzed proteins. Total HSP70 (HSP72 ? HSP73) protein content in the skeletal muscle was not changed (Fig. 5) in any experimental group.
Discussion
The main finding of this study was that HFD induced a mild insulin resistance and obesity in B6.129SF2/J mice but these metabolic changes were not reversed or improved by long-term L-glutamine or alanyl-L-glutamine supplementation. As discussed below, we argue that, unlike the C57BL/6J mouse model [24, 25] , in which genetically predisposition to become overweight developing hyperglycemia if raised on a HFD (please, see supplemental Fig. S1 ), the B6.129SF2/J mouse seems to be more resistant to the effects of HFD; perhaps due to changes in the gut nutrient absorption that, somehow, is able to protect these animals from the HFD effects. Moreover, the same changes in intestinal absorption of lipids may have also affected the amino acid uptake, thus explaining, at least in Body weight, fat pad, blood biomarkers, muscle glutamine, liver glycogen, liver TBA-RS, and total glutathione of mice maintained on high-fat diet (HFD) for 20 weeks and supplemented or not for the last 8 weeks of water (HFD-Con), dipeptide L-alanyl-L-glutamine (HFD-Dip), L-alanine (HFD-Ala), L-glutamine (HFD-Gln) and with L-alanine plus L-glutamine in their free forms (HFD-Ala ? Gln). Data are the means ± SEM part, the failure of the amino acid supplementations to improve the metabolic status. The animals that underwent the HFD, as expected, increased their body mass in comparison with the animals in the standard diet. Previous work has demonstrated the beneficial effects of L-glutamine supplementation on glycemia, insulinemia, and body weight gain in HFD-fed mice [25] , and of L-alanyl-L-glutamine in pancreatic b-cell function, improving insulin secretion [35] . In our hands, however, supplementation with L-glutamine, L-alanine, Lalanyl-L-glutamine, or L-alanine plus L-glutamine did not change the increments in body weight. The divergence found between our study and the study conducted by Opara et al. [25] was the strain of mouse (C57BL/6J) used and the time schedule of HFD and amino acid supplementation. Amino acid supplementation may be efficient to act against the harmful metabolic effects of a HDF only if given in parallel with the fat diet; what was not the case herein. It seems that the efficacy of L-glutamine or L-alanyl-L-glutamine is dependent on the time when the supplementation is started. Following this, Prada et al. [36] have demonstrated that rats under HFD and concomitant L-glutamine supplementation, for two months, show reduction in adipose mass, consequently attenuating insulin resistance. In addition, it is important to state that C57BL/6J mice under HFD did not change intestinal fat absorption rate since no modification in the fecal fat excretion was found [25] . Whether the observed lack of response to the above supplementations is in fact related to the expression of PKCd in metabolic tissues of the animals, as stated in the Introduction section, is under evaluation in our laboratory. Since our intervention did not induce changes in food intake, we suppose that long-term HFD can induce modification in the gut nutrient absorption, such as of glucose and amino acids. Our data on the oral GTT suggest that this may be the case. As observed in Fig. 2 , plasma glucose peaks 30 min after the glucose administration in the STA group. Interestingly, in all HFD groups, this peak was absent, suggesting differential glucose absorption by the gut. This could be due to a modification in the activity of nutrient transporters and/or changes in the levels of release of incretins, such as GLP-1. In fact, when we tested IPGTT, the 30 min peak was present in all groups. It is also of note that, except for HFD-Ala and HFD-Gln (single amino acid-supplemented groups), all the remaining test groups appear to have more prominent ITT glycemic slopes than STA control groups. Indeed no statistical difference was found between slopes or AUC values, although some difference seems to exist. While we have no plausible explanation to that, further experiments with intestinal mucosa are currently being planned in our laboratory to settle this point. Interestingly, the same pattern was observed in a study investigating the effects of HFD, for twelve weeks, in Wistar rats [37] . Following that, weaned Balb C57BL/6 mice, that were placed under HFD for 2 months, presented lower glucose absorption by the co-transporter SGLT1 when compared with animals under control diet [38] . Proteomic analysis revealed that intestinal mucosa expresses lower levels of GLUT-2 and Na/K ATPase pump, suggesting a lower capacity for glucose uptake by the gut [38] .
From the present observations, we hypothesize that a similar mechanism could explain the absence of the amino acid effects that we found, i.e., our amino acid supplementations were not properly absorbed by the gut. This hypothesis is strengthened by studies on gut amino acid transport in animals on HFD [39] [40] [41] . For example, the SNAT-2 amino acid transporter was found to be reduced by L-glutamine supplementation [39, 40] . Another study that supports this conjecture was also conducted in C57BL6/J mice under HFD for 6 weeks [41] . In this study, the expression of the co-transporter H ? /peptide Slc15a1 (PEPT1), the major responsible for the absorption of dipeptides, was reduced [41] . In our work, we investigated the effects of L-glutamine and the dipeptide alanyl-L-glutamine after 5 months of HFD. Therefore, it is reasonable to suppose that the amino acids transporters could be considerably reduced when we started the supplementation and, for this reason, our intervention failed to improve the metabolic and molecular parameters investigated. In fact, as recently demonstrated, supplementation with L-glutamine and L-alanyl-L-glutamine, for 8 weeks, increases the concentration of L-glutamine in the skeletal muscle of exercised rats [21] . However and corroborating our proposition on HFD decreasing effect on amino acid and dipeptide absorption, our intervention with amino acids and L-alanyl-L-glutamine did not increase the levels of L-glutamine within the skeletal muscle, as was expected. In addition, HFD may not only change the absorption rates of the amino acids, but also their metabolism. For instance, liver from rats on cafeteria diet (14 weeks) was found to present a 41 % reduction on the activity of glutaminase, suggesting that obese rats have lower capacity to metabolize the dietary L-glutamine [42] .
The inability of amino acid supplementations to cause improvements in the lipid profile after HFD was also observed in Zucker rats receiving L-arginine and L-alanine for 12 weeks. As also observed in the present study, HFD induced an increase in total cholesterol without any change in plasma triacylglycerols and the supplementation failed to reverse those changes [43] . Our results also show that HFD alone, or in the presence of the amino acid supplementations, did not induce any change in the levels of Akt-p or the insulin receptor in the liver and skeletal muscle. Similar results were found in C57BL/6J mice that underwent HFD for 11 weeks [44] . Changes in Akt were observed only when the muscles were incubated win the presence of insulin. The fact that, in the present study, we did not test the tissue response to insulin after the treatment is a limitation of our work that deserves further evaluation which is currently under investigation. Regarding TLR4 expression, we aimed to assess whether HFD influenced the level of expression of this protein and whether the amino acid supplementation has any effect on it. However, no changes were observed at any circumstance. Studies analyzing TLR4 expression in response to HFD have shown that TLR is increased after the intervention [45, 46] . Interestingly, high-fructose HFD-fed mice do exhibit elevation of TLR4 expression after 8 weeks of treatment; however, after 16 weeks, TLR4 expression returned to the basal levels [47] . Thus, it seems that TLR4 expression may have a transitory behavior, increasing in response to HFD during the first weeks of the regimen but undergoing a downregulation in long-term treatment. Since we analyzed the expression of TLR4 only at the end of the 28th week, the expression of this protein may be already attenuated. The importance of the intracellular HSP70 for insulin sensitivity was previously discussed in the introduction. Basically, what is known about the levels of this protein in obesity and diabetes is that divergences exist regarding its location, being reduced intracellularly and increased in the extracellular compartment [18, 48] . Thus, in obese and diabetic people, it is expected that the levels of HSP70 on the skeletal muscle and liver are reduced, which is a marker of chronic inflammation. In our work, we found only changes in the liver, where the content of this protein is increased after the HFD, thus suggesting just a primary defensive response to the harmful effects of HFD. On the other hand, muscle levels of HSP70 did not change and the amino acid supplementations had no influence on this behavior. Similar results were found in exercised rats after L-alanyl-L-glutamine supplementation [49] . Interestingly, however, in the same B6.129F2/J mice, it has clearly been shown that, in some extreme situations (e.g., endotoxemia), in which body L-glutamine stores may be seriously compromised, oral supplementations with L-alanyl-L-glutamine dipeptide or its components (L-alanine plus L-glutamine in their free forms) result in upregulation of GSH reductase, GSH peroxidase and glutamate cysteine ligase mRNA expression in the mouse muscle [23] . These glutamineelicited alterations were found to be accompanied by a decrease in HSP70, which returned to normal values. As speculated by Cruzat et al. [23] , it is unknown whether these effects are due exclusively to L-glutamine or L-alanine, but previous studies [50, 51] have suggested that Lalanine present in the dipeptide or in its free form can spare glutamine metabolism in order for the latter to be used by high-demand tissues under endotoxemia. Consequently, Lglutamine (with the help of L-alanine) would have the metabolic opportunity to be utilized as a GSH precursor and an enhancer of HSF1 stability onto HSE in the promoter regions of HSP70 genes [23] . In addition, L-alanyl-Lglutamine has recently been shown to strongly protect rat pancreatic b-cells against inflammatory injury (another glutamine highly demanding situation) by reinforcing SIRT1-HuR-HSP70 axis [35] .
The possible effects of glutamine supplements over GSH-HSP70 axis may have additional deployments in diabetic states. Fully diabetic subjects (in which systemic chronic inflammation had long been established) normally present reduced plasma glutamine levels [52, 53] . On the other hand, pre-diabetic patients presenting just an insulin resistance state may have normal levels [54] .
Increments in HSP70 levels were also found after HFD in Wistar rats; not mice. Furthermore, the tissue analyzed was the skeletal muscle, not the liver [55] . Similar results were found in vervet monkeys that underwent HFD for 4 months [56] . Interestingly, a dual response was observed that was time-dependent. During the HFD intervention, these animals increased their muscular HSP70 contents. However, 6 years later, HSP70 was reduced. After a regression analysis, it was found that during the 4 months of intervention, glycemic levels were directly correlated with muscle HSP70 levels. However, 6 years later, the data indicated the opposite pattern [56] . Thus, it seems that while insulin resistance is not chronically sustained or not so severe, cells are still able to compensate increasing their HSP70 levels. After long-term insulin resistance, notwithstanding, stress response (i.e., HSP70 machinery) is blunted by the senescent effect of obesity [4, 10] and the levels of HSP70 fall [56] .
The importance of normal HSP70 machinery for proper insulin sensitivity was elegantly demonstrated in HFD-fed mice who overexpress HSP70 [57] . In these animals, inflammatory signaling associated with insulin resistance, hyperglycemia, and hyperinsulinemia was prevented. In our study, the higher expression of HSP70 in the liver of HFD animals may represent just a transitory response while the insulin resistance is not severe. In whatever way, it is expected that the HSP70 concentration would fall if the intervention was maintained for a longer period. The raised HSP70 in the liver may also explain the reduced levels of lipoperoxidation.
Conclusions
In conclusion, long-term L-glutamine and dipeptide alanyl-L-glutamine supplementation failed to improve metabolic status in the HFD-fed B6.129SF2/J mouse model. Apparently, B6.129SF2/J mice are more resistant to the harmful effects of HFD through a mechanism that may include gut adaptation, reducing the absorption of fat and other nutrients, including amino acids. This may explain the lack of improvements in the intervention proposed. The efficacy of L-glutamine and L-alanyl-L-glutamine to increase metabolic status and HSP70 expression in HFD-fed animals is not excluded. The efficiency of these compounds may be dependent on the time of supplementation, being more efficient if supplementation occurs in parallel to the HFD.
